Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

92.48 +0.14 (+0.16%)
Streaming Delayed Price Updated: 2:20 PM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Lifts Partial Clinical Hold On Gilead's MDS, AML Magrolimab Studies
The FDA has  
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Pummeled! These 5 Dividend Growth Stocks Are Down Big Time From Their 52 Week Highs
2022 has been nuts, right? After investing for more than a decade, I've never seen this kind of sustained daily volatility before. But, as always, I see short-term volatility as a long-term... 
Via Talk Markets
Where Gilead Sciences Stands With Analysts
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: 
Via Benzinga
Gilead's Yescarta Scores FDA Approval As First CAR T-Cell Therapy For Earlier Lymphoma
Via Benzinga
High Dividend 50: Gilead Sciences
Gilead is offering an all-time high dividend yield of 5.0% and is trading at a forward price-to-earnings ratio of 9.1. Unfortunately, there are good reasons behind these seemingly attractive features... 
Via Talk Markets
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 13.94%. Currently, Gilead Sciences has a market... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc raised the price target on Block, Inc. (NYSE: SQ) from $175 to $180. Block shares rose 2.8% to $137.42 in pre-market trading. 
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Investors Seek Second Act with Moderna Stock
MRNA stock struck gold with its Covid-19 vaccine but investors want to know if there are any other blockbusters in its pipeline. 
Via InvestorPlace
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
Via Benzinga
Ten Healthcare Companies With High Payout Ratio
The healthcare industry is among the biggest U.S. market segments in terms of market capitalization, but when it comes to dividend payouts, they rank very low. 
Via Talk Markets
10 Biggest Price Target Changes For Monday
Wells Fargo cut the price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $70 to $63. Gilead Sciences shares rose 0.4% to $59.91 in pre-market trading. 
Via Benzinga
What Cramer Thinks About Hims & Hers Health, Gilead Sciences And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Healthcare Realty Trust Incorporated (NYSE: HR) as the company’s merger with Healthcare Trust of America, Inc. 
Via Benzinga
Buy These 3 High-Yield Stocks If You're In Your 50s And Cruise Into Retirement
In your 50s and looking for age-appropriate investments? Fancy yourself some hefty income in lieu of big growth as you age? Want to glide into retirement and land on a sheet of big, safe, totally... 
Via Talk Markets
Todos Medical Acquires Lucrative NLC Assets For Pennies On The Dollar
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Moderna Rockets As It Attempts The Impossible: Vaccinating Against HIV
It hasn't been possible to vaccinate against HIV. Does Moderna stand a chance? 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.58% on an annualized basis. Buying $100 In GILD: 20 years ago, an investor could have... 
Via Benzinga
Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint
Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic... 
Via Benzinga
How A Mixed Breast Cancer Study Cast Doubt On Gilead's Immunomedics Buyout
Gilead's Trodelvy had mixed test results in patients with breast cancer. 
Via Investor's Business Daily
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
Gilead Hit By FDA Complete Response Letter For Lenacapavir In HIV Infection
The FDA has issued a complete response letter (CRL) for Gilead Sciences Inc's (NASDAQ: GILD) application for lenacapavir for heavily treated multi-drug... 
Via Benzinga
Where Gilead Sciences Stands With Analysts
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Tumble Following New Sanctions Against Russia
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones surged more than 800 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the... 
Via Talk Markets
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.